Erich Harnack (1852&#8211;1915) and a Short History of Apomorphine | Zendy

Pille Taba | Zendy; Andrew J. Lees | Zendy; Gerald Stern | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Erich Harnack (1852–1915) and a Short History of Apomorphine

Author(s) -

Pille Taba,

Andrew J. Lees,

Gerald Stern

Publication year - 2013

Publication title -

european neurology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.573

H-Index - 77

eISSN - 1421-9913

pISSN - 0014-3022

DOI - 10.1159/000346762

Subject(s) - apomorphine , pharmacology , medicine , in vivo , levodopa , animal model , neuroscience , dopaminergic , disease , endocrinology , parkinson's disease , dopamine , psychology , biology , microbiology and biotechnology

Apomorphine, now established as an efficacious therapy for refractory motor fluctuations in levodopa-treated Parkinson's disease, has a long and chequered history in medical and veterinary therapeutics. The preclinical in vivo pharmacological effects of apomorphine were first studied about 150 years ago following which the drug was introduced for the treatment of behavioural vices in domesticated animals. Erich Harnack's early pharmacological studies in Dorpat (now Tartu, Estonia), where he belonged to the pharmacological dynasty of Buchheim and Schmiedeberg, are of particular historical significance as he emphasised that while apomorphine had potent emetic effects, the drug also had complex effects on the central nervous system.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research